Onida, Francesco and de Wreede, Liesbeth C. and van Biezen, Anja and Eikema, Diderik-Jan and Byrne, Jenny L. and Iori, Anna P. and Schots, Rik and Jungova, Alexandra and Schetelig, Johannes and Finke, Juergen and Veelken, Hendrik and Johansson, Jan-Erik and Craddock, Charles and Stelljes, Matthias and Theobald, Matthias and Holler, Ernst and Schanz, Urs and Schaap, Nicolaas and Bittenbring, Joerg and Olavarria, Eduardo and Chalandon, Yves and Kroeger, Nicolaus (2017) Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. BRITISH JOURNAL OF HAEMATOLOGY, 177 (5). pp. 759-765. ISSN 0007-1048, 1365-2141
Full text not available from this repository. (Request a copy)Abstract
Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MUTATIONS; GENETICS; DISTINCT; CML; allogeneic transplantation; atypical chronic myeloid leukaemia; Myelodyslastic/Myeloproliferative Neoplasms (MDS/MPN); Ph-negative CML: BCR-ABL1-negative |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 13:10 |
| Last Modified: | 12 Feb 2019 13:11 |
| URI: | https://pred.uni-regensburg.de/id/eprint/799 |
Actions (login required)
 |
View Item |
